← Back to headlines
Sarepta reiterates 2026 revenue guidance and targets Cohort 8 data
Sarepta Therapeutics has reiterated its net product revenue guidance of $1.2 billion to $1.4 billion for 2026, while also aiming to release Cohort 8 data by the end of the year.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
